Peter Prato for The New York Times | Australian Drug Maker Has Low Profile but Powerful Backers in Washington By KATIE THOMAS Representatives Chris Collins and Tom Price and other power players have substantial investments in Innate Immunotherapeutics, a company with no approved drugs. |
No comments:
Post a Comment